← SynDRA
GSK-2636771
SynDRA canonical compound SYN0037972 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PIK3CB |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- PIK3CB INHIBITOR
- PI3-kinase p110-beta subunit inhibitor
- PI3K inhibitor
Drug classes
- Antineoplastic Agents
- Protein Kinase Inhibitors
Cross-references
Synonyms
- GSK2636771
- GSK 2636771
- 2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid
- UNII-DW94IAT0LS
- DW94IAT0LS
- 2-Methyl-1-((2-methyl-3-(trifluoromethyl)phenyl)methyl)-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid
- 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid
- lic acid
- XTKLTGBKIDQGQL-UHFFFAOYSA-N
- RefChem:144516
- DTXCID9082615
- PI3K-beta Inhibitor GSK2636771
- MFCD22417098
- C22H22F3N3O3
- MLS006011177
- GTPL7967
- orb1306552
- SCHEMBL1280998
- SCHEMBL29352801
- SCHEMBL29411881
- EX-A434
- GLXC-90128
- HMS3653H17
- HMS3673E13
- HMS3749O03
- BDBM50059637
- NSC768508
- NSC781258
- NSC800110
- s8002
- AKOS026750339
- CCG-269050
- CS-0747
- EBC-220134
- GSK 2636771 [WHO-DD]
- NSC-768508
- NSC-781258
- NSC-800110
Look up GSK-2636771 in the interactive SynDRA portal →